NCT00487188 - A Study to Evaluate the Safety and Efficacy of Adding Enfuvirtide to Oral Highly Active Antiretroviral Therapy (HAART) in Human Immunodeficiency Virus (HIV) Patients With Prior Treatment Experience | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

November 30, 2007

Study Completion Date

April 30, 2008

Conditions

HIV Infections

Interventions

DRUG

Enfuvirtide

90 mg subcutaneous injection twice a day

DRUG

Highly active antiretroviral treatment (HAART)

An oral HAART regimen of 3-5 antiretrovirals was chosen by the physician and patient, based on the patient's prior treatment history and genotypic antiretroviral resistance testing.

Trial Locations (39)

8091

Zurich

11009

Cadiz

12157

Berlin

14000

Mexico City

14004

Córdoba

20014

Donostia / San Sebastian

20127

Milan

20157

Milan

21005

Huelva

25123

Brescia

28034

Madrid

28041

Madrid

28046

Madrid

29010

Málaga

41013

Seville

44035

Nantes

44109

Cleveland

46014

Valencia

47307

Villeneuve-sur-Lot

50011

Bagno a Ripoli

52662

Ramat Gan

53127

Bonn

60596

Frankfurt am Main

70100

Bari

75018

Paris

75246

Dallas

78705

Austin

86021

Poitiers

91054

Erlangen

94275

Le Kremlin-Bicêtre

V6Z 2C7

Vancouver

00149

Roma

00185

Roma

1105 AZ

Amsterdam

5022 GC

Tilburg

08026

Barcelona

08036

Barcelona

08370

Barcelona

08901

Barcelona

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY